Immunotherapy for malignant glioma: current approaches and future directions

REFERENCES

• Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443–451
   PubMed Web of Science ®Google Scholar
• Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916–3924
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119–126
   PubMed Web of Science ®Google Scholar
• Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63: 8996–9006
   PubMed Web of Science ®Google Scholar
• Hermisson M, Strik H, Rieger J, et al. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 2000; 54: 1357–1365
   PubMed Web of Science ®Google Scholar
• Kato M, Herz F, Kato S, et al. Expression of stress-response (heat-shock) protein 27 in human brain tumors: an immunohistochem-ical study. Acta Neuropathol (Berl) 1992; 83: 420–422
   PubMed Web of Science ®Google Scholar
• Kato S, Morita T, Takenaka T, et al. Stress-response (heat-shock) protein 90 expression in tumors of the central nervous system: An immunohistochemical study. Acta Neuropathol (Berl) 1995; 89: 184–188
   PubMed Web of Science ®Google Scholar
• Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781–790
   PubMed Web of Science ®Google Scholar
• Nguyen MD, Julien JP, Rivest S. Innate immunity: The missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3: 216–227
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298–300
   PubMed Web of Science ®Google Scholar
• Janeway C, Travers P, Walport M, et al. Immunobiology: The immune system in health and disease. New York: Current Biology Publications, 1999
   Google Scholar
• Prins RM, Liau LM. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 2003; 53: 144–152; discus-sion 152-153
   PubMed Web of Science ®Google Scholar
• Lampson LA. Basic principles of CNS immunology. In: Youmans J, ed. Neurological surgery, Philadelphia: Saunders, 2002: pp. 673–688
   Google Scholar
• Cserr H, Knopf P. Cervical lymphatics, the blood brain barrier, and the immunoreactivity of the brain. In: Keane R, Hickey W, eds. Immunology of the nervous system, New York: Oxford University Press, 1997: pp. 134–154
   Google Scholar
• Aloisi F, Ria F, Penna G, et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. ] Immunol 1998; 160: 4671–4680
   PubMed Web of Science ®Google Scholar
• Aloisi F. Immune function of microglia. Glia 2001; 36: 165–179
   PubMed Web of Science ®Google Scholar
• Issazadeh S, Navikas V, Schaub M, et al. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo.] Immunol 1998; 161: 1104–1112
   PubMed Web of Science ®Google Scholar
• Williams K, Ulvestad E, Antel JP. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol 1994; 24: 3031-3037
   Google Scholar
• Hickey WE. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001; 36: 118–124
   PubMed Web of Science ®Google Scholar
• de Vos AF, van Meurs M, Brok HP, et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. ] Immunol 2002; 169: 5415–5423
   PubMed Web of Science ®Google Scholar
• Walker PR, Calzascia T, Schnuriger V, et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.] Immunol 2000; 165: 3128–3135
   PubMed Web of Science ®Google Scholar
• Hickey WE, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. ] Neurosci Res 1991; 28: 254–260
   PubMed Web of Science ®Google Scholar
• Lampson LA. Beyond inflammation: Site-directed immunother-apy. Immunol Today 1998; 19: 17–22
   PubMedGoogle Scholar
• Perry VH, Anthony DC, Bolton Si, et al. The blood-brain barrier and the inflammatory response. Mol Med Today 1997; 3: 335-341
   Google Scholar
• Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999; 100: 216–232
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech 2001; 52: 112–129
   PubMed Web of Science ®Google Scholar
• Gordon FL, Nguyen KB, White CA, et al. Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112: 15–27
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the ‘immunologically privileged’ central nervous system. Proc Natl Acad Sci U S A 1996; 93: 10399–10404
   PubMed Web of Science ®Google Scholar
• Gordon LB, Nolan SC, Cserr HE, et al. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: A new tumor model for regional central nervous system immunity. ] Immunol 1997; 159: 2399–2408
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, McGeer EG. Expression of the histocom-patibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 1988; 76: 550–557
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285–1291
   PubMed Web of Science ®Google Scholar
• Sethna MP, Lampson LA. Immune modulation within the brain: Recruitment of inflammatory cells and increased major histo-compatibility antigen expression following intracerebral injection of interferon-gamma. ] Neuroimmunol 1991; 34: 121–132
   PubMed Web of Science ®Google Scholar
• Phillips LM, Lampson LA. Site-specific control of T cell traffic in the brain: T cell entry to brainstem vs. hippocampus after local injection of IFN-gamma. J Neuroimmunol 1999; 96: 218–227
   PubMed Web of Science ®Google Scholar
• Phillips LM, Simon PJ, Lampson LA. Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus. J Comp Neurol 1999; 405: 322–333
   PubMed Web of Science ®Google Scholar
• Parney IF, Farr-Jones MA, Chang LJ, et al. Human glioma immunobiology in vitro: implications for immunogene therapy. Neurosurgery 2000; 46: 1169–77; discussion 77-8.
   PubMed Web of Science ®Google Scholar
• Weller M, Frei K, Groscurth P, et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94: 954–964
   PubMed Web of Science ®Google Scholar
• Ashley DM, Sampson JH, Archer GE, et al. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. J Neuroimmunol 1997; 78: 34–46
   PubMed Web of Science ®Google Scholar
• Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melano-mas and gliomas. Am] Pathol 1997; 150: 2143–2152
   PubMed Web of Science ®Google Scholar
• Kurpad SN, Zhao XG, Wikstrand CJ, et al. Tumor antigens in astrocytic gliomas. Glia 1995; 15: 244–256
   PubMed Web of Science ®Google Scholar
• McLendon RE, Wikstrand CJ, Matthews MR, et al. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000; 48: 1103–1110
   PubMed Web of Science ®Google Scholar
• Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000; 97: 7503–7508
   PubMed Web of Science ®Google Scholar
• Holladay FP, Heitz T, Chen YL, et al. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992; 31: 528–533
   PubMed Web of Science ®Google Scholar
• Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36: 180–190
   PubMed Web of Science ®Google Scholar
• Carpentier PA, Begolka WS, Olson JK, et al. Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 2004; 49: 360–374
   Web of Science ®Google Scholar
• Aloisi F, Penna G, Cerase J, et al. IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997; 159: 1604–1612
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ohmori K, Fujiwara M. Immune regulation by brain cells in the central nervous system: Microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 1992; 76: 209–216
   PubMed Web of Science ®Google Scholar
• Ito A, Shinkai M, Honda H, et al. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001; 50: 515–522
   PubMed Web of Science ®Google Scholar
• Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front Biosci 2004; 9: 3124–3136
   PubMed Web of Science ®Google Scholar
• Yang I, Kremen TJ, Giovannone AJ, et al. Modulation of major histocompatibility complex Class I molecules and major histo-compatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 2004; 100: 310–319
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. ] Immunol 2002; 168: 4772–4780
   PubMed Web of Science ®Google Scholar
• Amiot L, Onno M, Lamy T, et al. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br] Haematol 1998; 100: 655–663
   PubMed Web of Science ®Google Scholar
• Luboldt HJ, Kubens BS, Rubben H, et al. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 1996; 56: 826–830
   PubMed Web of Science ®Google Scholar
• Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225–1237
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: A role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 2003; 13: 343–351
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867–1870
   PubMed Web of Science ®Google Scholar
• Prins RM, Scott GP, Merchant RE, et al. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother 2002; 51: 190–199
   PubMed Web of Science ®Google Scholar
• Morford LA, Elliott LH, Carlson SL, et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. ] Immunol 1997; 159: 4415–4425
   PubMed Web of Science ®Google Scholar
• Prins RM, Graf MR, Merchant RE. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 2001; 50: 285–292
   PubMed Web of Science ®Google Scholar
• Morford LA, Dix AR, Brooks WH, et al. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors. ] Neurosurg 1999; 91: 935–946
   PubMed Web of Science ®Google Scholar
• Brooks WH, Latta RB, Mahaley MS, et al. Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. ] Neurosurg 1981; 54: 331–337
   PubMed Web of Science ®Google Scholar
• Elliott LH, Brooks WH, Roszman TL. Activation of immunor-egulatory lymphocytes obtained from patients with malignant gliomas. ] Neurosurg 1987; 67: 231–236
   PubMed Web of Science ®Google Scholar
• Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991; 12: 370–374
   PubMedGoogle Scholar
• Olofsson A, Miyazono K, Kanzaki T, et al. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992; 267: 19482–19488
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Hamou ME, Sawamura Y, et al. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. ] Neurosurg 1989; 71: 211–217
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Roberts AB, Wakefield LM, et al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137: 3855–3860
   PubMed Web of Science ®Google Scholar
• Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon respon-siveness. J Immunol 1986; 136: 3916–3920
   PubMed Web of Science ®Google Scholar
• Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992; 148: 277–284
   PubMed Web of Science ®Google Scholar
• Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. ] Exp Med 1987; 166: 991–998
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037–1050
   PubMed Web of Science ®Google Scholar
• Garcia CM, Darland DC, Massingham 14, et al. Endothelial cell-astrocyte interactions and TGF beta are required for induction of blood-neural barrier properties. Brain Res Dev Brain Res 2004; 152: 25–38
   Google Scholar
• Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1988; 18: 1623–1626
   PubMed Web of Science ®Google Scholar
• Resnicoff M, Sell C, Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218–2222
   PubMed Web of Science ®Google Scholar
• Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg Neurol 1998; 49: 189–195; discussion 196
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tanaka R, Yoshida S, et al. Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. ] Neurooncol 1999; 43: 27–34
   PubMed Web of Science ®Google Scholar
• Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004; 3: 737–745
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Sawamura Y, Hamou ME, etal. Influence of PGE2-and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J Neurosurg 1990; 72: 619–625
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. Reversal of tumor-induced immunosuppres-sion by TGF-beta inhibitors. Invest New Drugs 2003; 21: 21–32
   PubMed Web of Science ®Google Scholar
• Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37: 1160–1166; discussion 1166-1167
   PubMed Web of Science ®Google Scholar
• Huettner C, Czub S, Kerkau S, et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 1997; 17: 3217–3224
   PubMed Web of Science ®Google Scholar
• Berman RM, Suzuki T, Tahara H, et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. ] Immunol 1996; 157: 231–238
   PubMed Web of Science ®Google Scholar
• Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321–1324
   PubMed Web of Science ®Google Scholar
• Krakowski ML, Owens T. The central nervous system environ-ment controls effector CD4+ T cell cytokine profile in experi-mental allergic encephalomyelitis. Eur J Immunol 1997; 27: 2840–2847
   PubMed Web of Science ®Google Scholar
• Glick RP, Lichtor T, de Zoeten E, et al. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secret-ing interleukin-2. Neurosurgery 1999; 45: 867–874
   PubMed Web of Science ®Google Scholar
• Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 1999; 6: 219–226
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2003; 188: 147–154
   Web of Science ®Google Scholar
• Sampath P, Hanes J, DiMeco F, et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 1999; 59: 2107–2114
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Giovarelli M, Modesti A, et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and develop-ment of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. ] Immunol 1994; 153: 4604–4615
   PubMed Web of Science ®Google Scholar
• Hiroishi K, Tuting T, Tahara H, et al. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumor-igen icity and growth of established tumor in poorly immunogenic tumor models. Gene Ther 1999; 6: 1988–1994
   PubMed Web of Science ®Google Scholar
• Horton HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A 1999; 96: 1553–1558
   PubMed Web of Science ®Google Scholar
• Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003; 171: 600–607
   PubMed Web of Science ®Google Scholar
• Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999; 6: 808–815
   PubMed Web of Science ®Google Scholar
• Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. ] Immunol 1995; 154: 6466–6474
   PubMed Web of Science ®Google Scholar
• Lumniczky K, Desaknai S, Mangel L, et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002; 9: 44–52
   PubMed Web of Science ®Google Scholar
• Okada H, Pollack IF. Cytokine gene therapy for malignant gl ioma. Expert Opin Biol Ther 2004; 4: 1609-1620
   Google Scholar
• Yu JS, Burwick JA, Dranoff G, et al. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997; 8: 1065–1072
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Abe J, Tsunoda R, et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996; 56: 1828–1833
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm CM, Johnston KM, et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997; 4: 345–352
   PubMed Web of Science ®Google Scholar
• Lefranc F, Cool V, Velu T, et al. Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 2002; 20: 1077–1085
   PubMed Web of Science ®Google Scholar
• Parney IF, Farr-Jones MA, Kane K, et al. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12. Can J Neurol Sci 2002; 29: 267–275
   PubMed Web of Science ®Google Scholar
• Parney IF, Petruk KC, Zhang C, et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997; 8: 1073–1085
   PubMed Web of Science ®Google Scholar
• Wallenfriedman MA, Conrad JA, DelaBarre L, et al. Effects of continuous localized infusion of granulocyte-macrophage col-ony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. ] Neurosurg 1999; 90: 1064–1071
   PubMed Web of Science ®Google Scholar
• Jean WC, Spellman SR, Wallenfriedman MA, et al. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunother-apy against intracranial glioma in the rat.] Neurooncol 2004; 66: 39–49
   PubMed Web of Science ®Google Scholar
• Sobol RE, Fakhrai H, Shawler D, et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 1995; 2: 164–167
   PubMed Web of Science ®Google Scholar
• Lichtor T, Glick RP. Cytokine immuno-gene therapy for treatment of brain tumors. J Neurooncol 2003; 65: 247–259
   PubMed Web of Science ®Google Scholar
• Glick RP, Lichtor T, Panchal R, et al. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the develop-ment of malignant brain tumors. J Neurooncol 2003; 64: 139–146
   PubMed Web of Science ®Google Scholar
• Lichtor T, Glick RP, Tarlock K, et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002; 9: 464–469
   PubMed Web of Science ®Google Scholar
• lwadate Y, Yamaura A, Sato Y et al. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors. Cancer Res 2001; 61: 8769–8774
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Takano S, et al. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intra-dermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci 2004; 95: 98–103
   PubMed Web of Science ®Google Scholar
• Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer ([AK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27: 398–404
   PubMed Web of Science ®Google Scholar
• Rhines LD, Sampath P, DiMeco F, et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer micro-spheres combined with interstitial chemotherapy: A novel treatment for experimental malignant glioma. Neurosurgery 2003; 52: 872–879; discussion 879-880
   PubMed Web of Science ®Google Scholar
• Okada H, Villa L, Attanucci J, et al. Cytokine gene therapy of gliomas: Effective induction of therapeutic immunity to intracra-nial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 2001; 8: 1157–1166
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: Preliminary observations in a patient with a favorable response to therapy. ] Neurooncol 2003; 64: 13–20
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Namba H, Sakiyama S, et al. Interleukin-12-mediated induction of systemic immunity in the periphery and recruitment of activated T cells into the brain produce limited antitumor effects compared with interleukin-2. Int J Mol Med 2002; 10: 741–747
   PubMed Web of Science ®Google Scholar
• DiMeco F, Rhines LD, Hanes J, et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.] Neurosurg 2000; 92: 419–427
   PubMed Web of Science ®Google Scholar
• Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol 2004; 23: 381–389
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62: 5657–5663
   PubMed Web of Science ®Google Scholar
• Roy EJ, Gawlick U, Orr BA, et al. IL-12 treatment of endogenously arising murine brain tumors. J Immunol 2000; 165: 7293–7299
   PubMed Web of Science ®Google Scholar
• Kishima H, Shimizu K, Miyao Y, et al. Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system. Br] Cancer 1998; 78: 446–453
   PubMed Web of Science ®Google Scholar
• Ni HT, Spellman SR, Jean WC, et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gl iomas. J Neurooncol 2001; 51: 1–9
   PubMed Web of Science ®Google Scholar
• Insug O, Ku G, Ertl HC, et al. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22: 613–621
   PubMed Web of Science ®Google Scholar
• Saito R, Mizuno M, Nakahara N, et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 2004; 111: 777–782
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. ] lmmunother 2004; 27: 452–459
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br] Cancer 2004; 91: 1656–1662
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br] Cancer 2003; 89: 1172–1179
   PubMed Web of Science ®Google Scholar
• de Vleeschouwer S, van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: Treatment with combination therapy including dendritic cell therapy. Case report.] Neurosurg Spine 2004; 100: 492–497
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973–4979
   PubMed Web of Science ®Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842–847
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol 2004; 6: 236–246
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, et al. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol lmmunother 2002; 51: 424–430
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Gutierrez MA, et al. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J lmmunother 2003; 26: 107–116
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tsuchiya N, Yajima N, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 2003; 99: 746–753
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Yajima N, Tsuchiya N, et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. J Neurosurg 2002; 97: 1184–1190
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000; 7: 867-74
   Google Scholar
• Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376
   PubMed Web of Science ®Google Scholar
• Ganly I, Kim D, Eckhardt G, et al. A phase I study of Onyx-015, an El B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–806
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. 0NYX-015, an El B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–645
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an El B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000; 60: 6359–6366
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an El B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958–966
   PubMed Web of Science ®Google Scholar
• Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448–453
   PubMed Web of Science ®Google Scholar
• Phuangsab A, Lorence RM, Reichard KW, et al. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 2001; 172: 27-36
   Google Scholar
• Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994; 54: 6017–6021
   PubMed Web of Science ®Google Scholar
• Lorence RM, Reichard KW, Katubig BB, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. I Natl Cancer Inst 1994; 86: 1228–1233
   PubMed Web of Science ®Google Scholar
• Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999; 281: 1588–1589
   PubMed Web of Science ®Google Scholar
• Csatary LK, Gosztonyi G, Szeberenyi J, et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004; 67: 83–93
   PubMed Web of Science ®Google Scholar
• Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334
   PubMed Web of Science ®Google Scholar
• Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001; 93: 903–912
   PubMed Web of Science ®Google Scholar
• Shah AC, Benos D, Gillespie GY, et al. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003; 65: 203–226
   PubMed Web of Science ®Google Scholar
• Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222–228
   PubMed Web of Science ®Google Scholar
• Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 97: 2208–2213
   PubMed Web of Science ®Google Scholar
• Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5: 121–130
   PubMed Web of Science ®Google Scholar
• Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002; 9: 9–15
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Kajiwara K, Ideguchi M, et al. Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4. Cancer Immunol Immunother 2000; 49: 23–33
   PubMed Web of Science ®Google Scholar
• Yamini B, Yu X, Gillespie GY, et al. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolo-mide in experimental glioblastoma. Cancer Res 2004; 64: 6381–6384
   PubMed Web of Science ®Google Scholar
• Chen B, Timiryasova TM, Haghighat P, et al. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. I Immunother 2001; 24: 46–57
   PubMed Web of Science ®Google Scholar
• Puri RK, Leland P, Kreitman RJ, et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994; 58: 574–581
   PubMed Web of Science ®Google Scholar
• Joshi BH, Leland P, Silber J, et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br] Cancer 2002; 86: 285–291
   PubMed Web of Science ®Google Scholar
• Joshi BH, Leland P, Asher A, et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblas-toma cell cultures. Cancer Res 2001; 61: 8058–8061
   PubMed Web of Science ®Google Scholar
• Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. I Neurooncol 2003; 64: 125–137
   PubMed Web of Science ®Google Scholar
• Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003; 88: 93–103
   PubMedGoogle Scholar
• Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. I Neurooncol 2003; 65: 15–25
   PubMed Web of Science ®Google Scholar
• Rainov NG, Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). I Neurooncol 2004; 66: 197–201
   PubMed Web of Science ®Google Scholar
• Debinski W, Obiri NI, Powers SK, et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995; 1: 1253–1258
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5: 985–990
   PubMed Web of Science ®Google Scholar
• Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88: 105–111
   PubMedGoogle Scholar
• Graf MR, Prins RM, Poulsen GA, et al. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: Accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. I Neuroimmunol 2003; 140: 49–60
   PubMed Web of Science ®Google Scholar
• Saleh M, Wiegmans A, Malone Q, et al. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. I Natl Cancer Inst 1999; 91: 438–445
   PubMed Web of Science ®Google Scholar
• Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. Virol 1999; 73: 6319–6326
   Web of Science ®Google Scholar
• Kesari S, Randazzo BP, Valyi-Nagy T, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636–648
   PubMed Web of Science ®Google Scholar
• Randazzo BP, Kesari S, Gesser RM, et al. Treatment of experimental intracranial murine melanoma with a neuroatte-nuated herpes simplex virus 1 mutant. Virology 1995; 211: 94–101
   PubMed Web of Science ®Google Scholar
• Valyi-Nagy T, Fareed MU, O'Keefe is, et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. I Gen Virol 1994; 75 (Pt 8): 2059-2063
   Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859–866
   PubMed Web of Science ®Google Scholar
• Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 2004; 11: 1648–1658
   PubMed Web of Science ®Google Scholar
• Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malig-nant glioma: A proof of principle study. Gene Ther 2002; 9: 398-406
   Google Scholar
• Lorence RM, Pecora AL, Major PP, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003; 5: 618–624
   PubMed Web of Science ®Google Scholar
• Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prey 1993; 17: 619–627
   PubMedGoogle Scholar
• Yang WQ, Lun X, Palmer CA, et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576
   PubMed Web of Science ®Google Scholar
• Oncolytics Biotech releases REOLYSIN phase I clinical trial results. Expert Rev Anticancer Ther 2002; 2: 139
   Google Scholar
• Wei MX, Li F, Ono Y, et al. Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. Neurovirol 1998; 4: 237–241
   PubMed Web of Science ®Google Scholar